Advertisement

European Journal of Clinical Pharmacology

, Volume 31, Issue 2, pp 143–147 | Cite as

Effects of single oral doses of bisoprolol and atenolol on airway function in nonasthmatic chronic obstructive lung disease and angina pectoris

  • P. Dorow
  • H. Bethge
  • U. Tönnesmann
Originals

Summary

A randomized, placebo-controlled, double-blind crossover investigation in 12 patients with non-asthmatic chronic obstructive lung disease and co-existing stable angina pectoris was done to compare two β1-selective adrenoceptor blocking agents, atenolol 100 mg and bisoprolol 20 mg. Systolic and diastolic blood pressures (SBP, DBP), heart rate (HR) as well as airway resistance (AWR, and less frequently forced expiratory volume in 1 s (FEV1) and intrathoracic gas volume (ITGV) were measured in the sitting position before and at various times up to 24 h after drug intake.

During the first 4 h both beta-blockers produced a significant reduction in HR in comparison to placebo (p<0.01). Atenolol 100 mg significantly increased AWR relative to placebo and bisoprolol (p<0.05). After 24 h, a significant reduction in HR (p<0.01) could only be demonstrated after bisoprolol, whereas atenolol alone led to a significant elevation in AWR relative to placebo and bisoprolol (p<0.05) at that time.

It is concluded that bisoprolol appears to have a high degree of beta1-selectivity, thus providing a wide split between beta1- and beta2-adrenoceptor blockade. Bisoprolol in its therapeutic dose range is expected to be relatively safe as regards bronchoconstriction in patients suffering both from hypertension and/or angina pectoris and chronic obstructive lung disease.

Key words

bisoprolol atenolol angina pectoris β1-/ β2-blockade selectivity lung function parameters non-asthmatic chronic obstructive lung disease 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Barnett DB, Rugg EL, Nahorski SR (1978) Direct evidence of two types of β-adrenoceptor binding site in lung tissue. Nature 273: 166–168Google Scholar
  2. 2.
    Benson MK, Berrill WT, Cruickshank JM, Sterling GS (1978) A comparison of four β-adrenoceptor antagonists in patients with asthma. Br J Clin Pharmacol 5: 415–419Google Scholar
  3. 3.
    Brown HC, Carruthers SG, Johnston GD, Kelly JG, McAinsh J, McDevitt DG, Shanks RG (1976) Clinical pharmacologic observations on atenolol, a beta-adrenoceptor blocker. Clin Pharmacol Ther 20: 524–534Google Scholar
  4. 4.
    Chatterjee SS (1985) The cardioselective and hypotensive effects of bisoprolol in hypertensive asthmatics. Abstract Cardiovascular Pharmacotherapy International Symposium 1985, Geneva, April 22–25, 1985Google Scholar
  5. 5.
    Chester EH, Schwartz HJ, Fleming GM (1981) Adverse effect of propranolol on airway function in nonasthmatic chronic obstructive lung disease. Chest 79: 540–544Google Scholar
  6. 6.
    Decalmer PBS, Chatterjee SS, Cruickshank JM, Benson MK, Sterling GM (1978) Beta-blockers and asthma. Br Heart J 40: 184–189Google Scholar
  7. 7.
    McDevitt DG (1978) β-adrenoceptor antagonists and respiratory function. Br J Clin Pharmacol 5: 97–99Google Scholar
  8. 8.
    Dorow P, Tönnesmann U (1984) Dose-response relationship for the β-adrenoceptor antagonist bisoprolol in patients with coronary heart disease and chronic obstructive bronchitis. Eur J Clin Pharmacol 27: 135–139Google Scholar
  9. 9.
    Fitzgerald JD, Ruffin R, Smedstad KG, Roberts R, McAinsh J (1978) Studies on the pharmacokinetics and pharmacodynamics of atenolol in man. Eur J Clin Pharmacol 13: 81–89Google Scholar
  10. 10.
    Formgren H (1976) The effect of metoprolol and practolol on lung function and blood pressure in hypertensive asthmatics. Br J Clin Pharmacol 3: 1007–1014Google Scholar
  11. 11.
    Gribbin HR, Baldwin CJ, Tattersfield AE (1979) Quantitative assessment of bronchial β-adrenoceptor blockade in man. Br J Clin Pharmacol 7: 551–556Google Scholar
  12. 12.
    Van Herwaarden CLA (1983), β-adrenoceptor blockade and pulmonary function in patients suffering from chronic obstructive lung disease. J Cardiovasc Pharmacol 5: 46–50Google Scholar
  13. 13.
    Jackson SHD, Beevers DG (1983) Comparison of the effects of single doses of atenolol and labetalol on airways obstruction in patients with hypertension and asthma. Br J Clin Pharmacol 15: 553–556Google Scholar
  14. 14.
    Lammers JWJ, Folgering HTM, von Herwaarden CLA (1984) Ventilatory effects of beta1-receptor-selective blockade with bisoprolol and metoprolol in asthmatic patients. Eur J Clin Pharmacol 27: 141–145Google Scholar
  15. 15.
    Lawrence DS, Sahay JN, Chatterjee SS, Cruickshank JM (1982) Asthma and beta-blockers. Eur J Clin Pharmacol 22: 501–509Google Scholar
  16. 16.
    Leopold G, Pabst J, Ungethüm W, Bühring KU (1985) Basic pharmacokinetics of bisoprolol, a new highly beta1-selective adrenoceptor antagonist. Clin Pharmacol Ther (in press)Google Scholar
  17. 17.
    Manalan AS, Besch HR, Watanabe AM (1981) Characterization of (3H) (±) carazolol binding to β-adrenergic receptors. Circ Res 49: 326–336Google Scholar
  18. 18.
    Sorbini CA, Grassi V, Tantucci C, Todisco T, Motolese M & Verdecchia P (1982) Acute effects of oral metoprolol on ventilatory function in patients with chronic obstructive lung disease. Acta Ther 8: 5–16Google Scholar
  19. 19.
    Schliep HJ, Harting J (1984) Beta1-selectivity of bisoprolol, a new β-adrenoceptor antagonist, in anaesthetized dogs and guinea pigs. J Cardiovasc Pharmacol 6: 1156–1160Google Scholar
  20. 20.
    Tattersfield AE, Cragg DJ, Bacon RJ (1984) Assessment of β-adrenoceptor selectivity of a new β-adrenoceptor antagonist, bisoprolol, in man. Br J Clin Pharmacol 18: 343–347Google Scholar

Copyright information

© Springer-Verlag 1986

Authors and Affiliations

  • P. Dorow
    • 1
  • H. Bethge
    • 1
  • U. Tönnesmann
    • 1
  1. 1.Lung Function Laboratory, Department of Cardiology and PulmonologyUniversity ClinicBerlin-CharlottenburgGermany

Personalised recommendations